For novel pneumonia, i.e., pneumonia caused by novel coronavirus infection, two therapeutic drugs have been preliminarily screened for this disease, which can effectively inhibit the replication of novel coronavirus at the cellular level, and their effects in humans are pending clinical trials. Antiviral therapy can be tried with alpha-interferon nebulized inhalation or oral lopinavir or ritonavir. In severe cases, glucocorticoids are used for a short period (3-5 days) as appropriate, and vasoactive drugs may also be used to improve microcirculation. To maintain intestinal microecological balance and prevent secondary bacterial infections, intestinal microecological regulators can be used.